TerminatedPHASE1, PHASE2NCT04425070
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
Studying Extranodal nasal NK/T cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Antengene Corporation
- Principal Investigator
- Yang Yu, MDMedical Director
- Intervention
- ICE [ifosfamide+carboplatin+etoposide](combination_product)
- Enrollment
- 56 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2025
Study locations (13)
- Anhui Provincial Cancer Hospital, Hefei, Anhui, China
- Beijing Tongren Hospital.CMU, Beijing, Beijing Municipality, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Hubei Cancer Hospital, Wuhan, Hubei, China
- Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
- Jiangsu Province Hospital, Nanjing, Jiangsu, China
- Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
- Tianjin Medical Universisity Cancer Institute & Hospital, Tianjin, Tianjin Municipality, China
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04425070 on ClinicalTrials.govOther trials for Extranodal nasal NK/T cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07380984PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06966154A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLFudan University
- RECRUITINGPHASE2NCT07000617A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell LymphomaPeking University Cancer Hospital & Institute
- RECRUITINGPHASE1NCT06732492RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ENROLLING BY INVITATIONNCT07450040Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell LymphomaEye & ENT Hospital of Fudan University
- RECRUITINGPHASE1, PHASE2NCT06559553"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCLMingzhi Zhang
- RECRUITINGPHASE2NCT06824883Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell LymphomaPeking Union Medical College Hospital
- RECRUITINGPHASE1, PHASE2NCT06376721Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaBeijing Tongren Hospital